Nutex Health (NUTX) to Release Earnings on Monday

Key Points

• Nutex Health will release Q1 2026 results after the market close on Monday, May 4; analysts forecast EPS of $3.99 and revenue of $227.801 million, and the company lists an earnings call for May 1 at 10:30 AM ET.
• In the prior quarter (reported March 5) Nutex missed expectations, reporting EPS of $1.61 versus a $5.56 consensus and revenue of $151.68M versus $258.82M expected.
• Analysts hold a “Moderate Buy” consensus with a $252.50 price target; the stock opened at $108.24, has a market cap of $754.4M and a P/E of 12.05, and institutional ownership is roughly 5.3%.

Nutex Health (NASDAQ:NUTX - Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect Nutex Health to post earnings of $3.99 per share and revenue of $227.8010 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 1, 2026 at 10:30 AM ET.

Nutex Health (NASDAQ:NUTX - Get Free Report) last posted its earnings results on Thursday, March 5th. The company reported $1.61 earnings per share for the quarter, missing analysts' consensus estimates of $5.56 by ($3.95). The company had revenue of $151.68 million for the quarter, compared to analysts' expectations of $258.82 million. Nutex Health had a return on equity of 17.67% and a net margin of 7.34%.

Nutex Health Price Performance

Nutex Health stock opened at $108.24 on Monday. The business has a fifty day moving average of $101.25 and a two-hundred day moving average of $126.24. The company has a quick ratio of 3.39, a current ratio of 3.41 and a debt-to-equity ratio of 0.70. The firm has a market cap of $754.43 million, a P/E ratio of 12.05 and a beta of 0.10. Nutex Health has a twelve month low of $77.21 and a twelve month high of $193.07.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NUTX. Wall Street Zen lowered Nutex Health from a "strong-buy" rating to a "hold" rating in a report on Saturday, March 7th. Weiss Ratings reissued a "hold (c)" rating on shares of Nutex Health in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $252.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Nutex Health in the 4th quarter worth $319,000. Franklin Resources Inc. purchased a new position in Nutex Health in the 3rd quarter worth $233,000. Captrust Financial Advisors purchased a new position in Nutex Health in the 2nd quarter worth $264,000. Raymond James Financial Inc. purchased a new position in Nutex Health in the 2nd quarter worth $142,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Nutex Health in the 2nd quarter worth $234,000. 5.32% of the stock is currently owned by hedge funds and other institutional investors.

Nutex Health Company Profile

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.